Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction

H. M. Chen*, J. C. Chen, T. L. Hwang, Y. Y. Jan, M. F. Chen

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

68 Scopus citations

Abstract

Background/Aims: Exaggerated production of various proteases may account for the late presence of organ dysfunction in acute pancreatitis. This study examined the effects of early administration of gabexate mesilate on the condition of patients with severe acute pancreatitis and organ dysfunctions. Methodology: Fifty-two patients with acute pancreatitis and organ dysfunction were enrolled. The treatment group included 26 patients receiving intravenous gabexate mesilate infusion at a dose of 100mg/hr for 7 days. APACHE-II score, clinical and biochemical parameters were monitored intensively. Results: Coagulopathy ileus, and abdominal pain was significantly improved with gabexate mesilate. Gabexate mesilate reduced the necessity for surgical intervention and peritoneal lavage. The 7-day-mortality and 90-day-mortality rates were also significantly reduced with gabexate mesilate therapy. Conclusions: There are strong indications from this study that early intravenous gabexate mesilate infusion results in improved survival in acute pancreatitis with organ dysfunctions.

Original languageEnglish
Pages (from-to)1147-1150
Number of pages4
JournalHepato-Gastroenterology
Volume47
Issue number34
StatePublished - 2000
Externally publishedYes

Keywords

  • APACHE-II score
  • Acute pancreatitis
  • Coagulopathy
  • Complication
  • Gabexate mesilate
  • Multiple organ dysfunction

Fingerprint

Dive into the research topics of 'Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction'. Together they form a unique fingerprint.

Cite this